CD47 is a Novel Potent Immunotherapy Target in Human Malignancies: Current Studies and Future Promises

References

• Adachi K , TamadaK. Immune checkpoint blockade opens an avenue of cancer immunotherapy with a potent clinical efficacy. Cancer Sci.106(8), 945–950 (2015).
   PubMed Web of Science ®Google Scholar
• Hamanishi J , MandaiM, MatsumuraN, AbikoK, BabaT, KonishiI. PD-1/PD-L1 blockade in cancer treatment: perspectives and issues. Int. J. Clin. Oncol.21(3), 462–473 (2016).
   PubMed Web of Science ®Google Scholar
• Wang X , BaoZ, ZhangXet al. Effectiveness and safety of PD-1/PD-L1 inhibitors in the treatment of solid tumors: a systematic review and meta-analysis. Oncotarget8(35), 59901–59914 (2017).
   PubMedGoogle Scholar
• Blank CU , EnkA. Therapeutic use of anti-CTLA-4 antibodies. Int. Immunol.27(1), 3–10 (2015).
   PubMed Web of Science ®Google Scholar
• Schupp J , KrebsFK, ZimmerN, TrzeciakE, SchuppanD, TuettenbergA. Targeting myeloid cells in the tumor sustaining microenvironment. Cell. Immunol. doi:10.1016/j.cellimm.2017.10.013 (2017) ( Epub ahead of print).
   PubMed Web of Science ®Google Scholar
• Rey-Giraud F , HafnerM, RiesCH. In vitro generation of monocyte-derived macrophages underserum-free conditions improves their tumor promoting functions. PLoS ONE7(8), e42656 (2012).
   PubMed Web of Science ®Google Scholar
• Cornelissen R , LievenseLA, MaatAPet al. Ratio of intratumoral macrophage phenotypes is a prognostic factor in epithelioid malignant pleural mesothelioma. PLoS ONE9(9), e106742 (2014).
   PubMed Web of Science ®Google Scholar
• Bronkhorst IH , LyLV, JordanovaESet al. Detection of M2-macrophages in uveal melanoma and relation with survival. Invest. Ophthalmol. Vis. Sci.52(2), 643–650 (2011).
   PubMed Web of Science ®Google Scholar
• Feng M , ChenJY, Weissman-TsukamotoRet al. Macrophages eat cancer cells using their own calreticulin as a guide: roles of TLR and Btk. Proc. Natl Acad. Sci. USA112(7), 2145–2150 (2015).
   PubMed Web of Science ®Google Scholar
• Liu X , PuY, CronKet al. CD47 blockade triggers T cell-mediated destruction of immunogenic tumors. Nat. Med.21(10), 1209–1215 (2015).
   PubMed Web of Science ®Google Scholar
• Sick E , JeanneA, SchneiderC, DedieuS, TakedaK, MartinyL. CD47 update: a multifaceted actor in the tumour microenvironment of potential therapeutic interest. Br. J. Pharmacol.167(7), 1415–1430 (2012).
   PubMed Web of Science ®Google Scholar
• Mordue KE , HawleyBR, SatchwellTJ, ToyeAM. CD47 surface stability is sensitive to actin disruption prior to inclusion within the band 3 macrocomplex. Sci. Rep.7(1), 2246 (2017).
   PubMedGoogle Scholar
• Barclay AN , Van den BergTK. The interaction between signal regulatory protein alpha (SIRPα) and CD47: structure, function, and therapeutic target. Annu. Rev. Immunol.32, 25–50 (2014).
   PubMed Web of Science ®Google Scholar
• Oldenborg PA , GreshamHD, ChenY, IzuiS, LindbergFP. Lethal autoimmune haemolytic anemia in CD47-deficient nonobese diabetic (NOD) mice. Blood99(10), 3500–3504 (2002).
   PubMed Web of Science ®Google Scholar
• Olsson M , BruhnsP, FrazierWA, RavetchJV, OldenborgPA. Platelet homeostasis is regulated by platelet expression of CD47 under normal conditions and in passive immune thrombocytopenia. Blood105(9), 3577–3582 (2005).
   PubMed Web of Science ®Google Scholar
• Jaiswal S , JamiesonCH, PangWWet al. CD47 is upregulated on circulating hematopoietic stem cells and leukemia cells to avoid phagocytosis. Cell138(2), 271–285 (2009).
   PubMed Web of Science ®Google Scholar
• Yoshida K , TsujimotoH, MatsumuraKet al. CD47 is an adverse prognostic factor and a therapeutic target in gastric cancer. Cancer Med.4(9), 1322–1333 (2015).
   PubMed Web of Science ®Google Scholar
• Liu R , WeiH, GaoPet al. CD47 promotes ovarian cancer progression by inhibiting macrophage phagocytosis. Oncotarget8(24), 39021–39032 (2017).
   PubMedGoogle Scholar
• Li Y , LuS, XuYet al. Overexpression of CD47 predicts poor prognosis and promotes cancer cell invasion in high-grade serous ovarian carcinoma. Am. J. Transl. Res.9(6), 2901–1910 (2017).
   PubMed Web of Science ®Google Scholar
• Galli S , ZlobecI, SchürchC, PerrenA, OchsenbeinAF, BanzY. CD47 protein expression in acute myeloid leukemia: a tissue microarray-based analysis. Leuk. Res.39(7), 749–756 (2015).
   PubMed Web of Science ®Google Scholar
• Starr JS , JiangL, LiZ, QiuY, MenkeDM, TunHW. CD47 and osteopontin expression in diffuse large B-cell lymphoma with nodal and intravascular involvement. Clin. Lymphoma Myeloma Leuk.13(5), 597–601 (2013).
   PubMed Web of Science ®Google Scholar
• Sudo T , TakahashiY, SawadaG, UchiR, MimoriK, AkagiY. Significance of CD47 expression in gastric cancer. Oncol. Lett.14(1), 801–809 (2017).
   PubMed Web of Science ®Google Scholar
• Xiao Z , ChungH, BananBet al. Antibody mediated therapy targeting CD47 inhibits tumor progression of hepatocellular carcinoma. Cancer Lett.360(2), 302–309 (2015).
   PubMed Web of Science ®Google Scholar
• Weiskopf K , JahchanNS, SchnorrPJet al. CD47-blocking immunotherapies stimulate macrophage-mediated destruction of small-cell lung cancer. J. Clin. Invest.126(7), 2610–2620 (2016).
   PubMed Web of Science ®Google Scholar
• Kaur S , ElkahlounAG, SinghSPet al. A function-blocking CD47 antibody suppresses stem cell and EGF signaling in triple-negative breast cancer. Oncotarget7(9), 10133–10152 (2016).
   PubMedGoogle Scholar
• Kaur S , Martin-MansoG, PendrakML, GarfieldSH, IsenbergJS, RobertsDD. Thrombospondin-1 inhibits VEGF receptor-2 signaling by disrupting its association with CD47. J. Biol. Chem.285(50), 38923–38932 (2010).
   PubMed Web of Science ®Google Scholar
• Kaur S , ChangT, SinghSPet al. CD47 signaling regulates the immunosuppressive activity of VEGF in T cells. J. Immunol.193(8), 3914–3924 (2014).
   PubMed Web of Science ®Google Scholar
• Rogers NM , Sharifi-SanjaniM, YaoMet al. TSP1-CD47 signaling is upregulated in clinical pulmonary hypertension and contributes to pulmonary arterial vasculopathy and dysfunction. Cardiovasc. Res.113(1), 15–29 (2017).
   PubMed Web of Science ®Google Scholar
• Murata Y , KotaniT, OhnishiH, MatozakiT. The CD47-SIRPα signalling system: its physiological roles and therapeutic application. J. Biochem.155(6), 335–344 (2014).
   PubMed Web of Science ®Google Scholar
• Matlung HL , SzilagyiK, BarclayNA, van den BergTK. The CD47-SIRPα signaling axis as an innate immune checkpoint in cancer. Immunol. Rev.276(1), 145–164 (2017).
   PubMed Web of Science ®Google Scholar
• Chao MP , WeissmanIL, MajetiR. The CD47-SIRPα pathway in cancer immune evasion and potential therapeutic implications. Curr. Opin. Immunol.24(2), 225–232 (2012).
   PubMed Web of Science ®Google Scholar
• Latour S , TanakaH, DemeureCet al. Bidirectional negative regulation of human T and dendritic cells by CD47 and its cognate receptor signal-regulator protein-alpha: down-regulation of IL-12 responsiveness and inhibition of dendritic cell activation. J. Immunol.167(5), 2547–2554 (2001).
   PubMed Web of Science ®Google Scholar
• Petty AJ , YangY. Tumor-associated macrophages: implications in cancer immunotherapy. Immunotherapy9(3), 289–302 (2017).
   PubMed Web of Science ®Google Scholar
• Becker M , MüllerCB, De BastianiMA, KlamtF. The prognostic impact of tumor-associated macrophages and intra-tumoral apoptosis in non-small cell lung cancer. Histol. Histopathol.29(1), 21–31 (2014).
   PubMed Web of Science ®Google Scholar
• Sakakura K , TakahashiH, KairaKet al. Relationship between tumor-associated macrophage subsets and CD47 expression in squamous cell carcinoma of the head and neck in the tumor microenvironment. Lab. Invest.96(9), 994–1003 (2016).
   PubMed Web of Science ®Google Scholar
• Weiskopf K . Cancer immunotherapy targeting the CD47/SIRPα axis. Eur. J. Cancer76, 100–109 (2017).
   PubMed Web of Science ®Google Scholar
• Zhang M , HutterG, KahnSAet al. Anti-CD47 treatment stimulates phagocytosis of glioblastoma by M1 and M2 polarized macrophages and promotes M1 polarized macrophages in vivo. PLoS ONE11(4), e0153550 (2016).
   PubMed Web of Science ®Google Scholar
• Métayer LE , VilaltaA, BurkeGAA, BrownGC. Anti-CD47 antibodies induce phagocytosis of live, malignant B cells by macrophages via the Fc domain, resulting in cell death by phagocytosis. Oncotarget8(37), 60892–60903 (2017).
   PubMedGoogle Scholar
• Kim MJ , LeeJC, LeeJJet al. Association of CD47 with natural killer cell-mediated cytotoxicity of head-and-neck squamous cell carcinoma lines. Tumour Biol.29(1), 28–34 (2008).
   PubMedGoogle Scholar
• Weiskopf K , RingAM, HoCCet al. Engineered SIRPα variants as immunotherapeutic adjuvants to anti-cancer antibodies. Science341(6141), 88–91 (2013).
   PubMed Web of Science ®Google Scholar
• Poels LG , PetersD, van MegenYet al. Monoclonal antibody against human ovarian tumor-associated antigens. J. Natl Cancer Inst.76(5), 781–791 (1986).
   PubMedGoogle Scholar
• Chao MP , AlizadehAA, TangCet al. Anti-CD47 antibody synergizes with rituximab to promote phagocytosis and eradicate non-Hodgkin lymphoma. Cell142(5), 699–713 (2010).
   PubMed Web of Science ®Google Scholar
• Liu X , PuY, CronKet al. CD47 blockade triggers T cell-mediated destruction of immunogenic tumors. Nat. Med.21(10), 1209–1215 (2015).
   PubMed Web of Science ®Google Scholar
• Gholamin S , MitraSS, FerozeAHet al. Disrupting the CD47-SIRPα anti-phagocytic axis by a humanized anti-CD47 antibody is an efficacious treatment for malignant pediatric brain tumors. Sci. Transl. Med.9(381), pii:eaaf2968 (2017).
   PubMed Web of Science ®Google Scholar
• Liu J , WangL, ZhaoFet al. Pre-clinical development of a humanized anti-CD47 antibody with anti-cancer therapeutic potential. PLoS ONE10(9), e0137345 (2015).
   PubMed Web of Science ®Google Scholar
• Sikic BI , NarayananS, ColevasADet al. A first-in-human, first-in-class Phase I trial of the anti-CD47 antibody Hu5F9-G4 in patients with advanced cancers. J. Clin. Oncol.34(Suppl.), Abstract 3019 (2016).
   Google Scholar
• Lameris R , de BruinRC, SchneidersFLet al. Bispecific antibody platforms for cancer immunotherapy. Crit. Rev. Oncol. Hematol.92(3), 153–165 (2014).
   PubMed Web of Science ®Google Scholar
• Piccione EC , JuarezS, LiuJet al. A bispecific antibody targeting CD47 and CD20 selectively binds and eliminates dual antigen expressing lymphoma cells. MAbs7(5), 946–956 (2015).
   PubMed Web of Science ®Google Scholar
• van Bommel PE , HeY, SchepelIet al. CD20-selective inhibition of CD47-SIRPa “don’t eat me” signaling with a bispecific antibody-derivative enhances the anticancer activity of daratumumab, alemtuzumab and obinutuzumab. Oncoimmunology7(2), e1386361 (2017).
   PubMed Web of Science ®Google Scholar
• Dheilly E , MoineV, BroyerLet al. Selective blockade of the ubiquitous checkpoint receptor CD47 is enabled by dual-targeting bispecific antibodies. Mol. Ther.25(2), 523–533 (2017).
   PubMed Web of Science ®Google Scholar
• Petrova PS , VillerNN, WongMet al. TTI-621 (SIRPαFc): a CD47-blocking innate immune checkpoint inhibitor with broad antitumor activity and minimal erythrocyte binding. Clin. Cancer Res.23(4), 1068–1079 (2017).
   PubMed Web of Science ®Google Scholar
• Ansell S , ChenRW, FlinnIWet al. A Phase 1 study of TTI-621, a novel immune checkpoint inhibitor targeting CD47, in patients with relapsed or refractory hematologic malignancies. Blood128(22), 1812 (2016).
   Google Scholar
• Cousin S , SeneschalJ, ItalianoA. Toxicity profiles of immunotherapy. Pharmacol. Ther.181, 91–100 (2018).
   PubMed Web of Science ®Google Scholar
• Arias CF , AriasCF. How do red blood cells know when to die?R. Soc. Open Sci.4(4), 160850 (2017).
   PubMed Web of Science ®Google Scholar
• Pietsch EC , DongJ, CardosoRet al. Anti-leukemic activity and tolerability of anti-human CD47 monoclonal antibodies. Blood Cancer J.7(2), e536 (2017).
   PubMedGoogle Scholar
• Casey SC , TongL, LiYet al. MYC regulates the antitumor immune response through CD47 and PD-L1. Science352(6282), 227–231 (2016).
   PubMed Web of Science ®Google Scholar
• Sockolosky JT , DouganM, IngramJRet al. Durable antitumor responses to CD47 blockade require adaptive immune stimulation. Proc. Natl Acad. Sci. USA113(19), 2646–2654 (2016).
   PubMed Web of Science ®Google Scholar
• Ingram JR , BlombergOS, SockoloskyJTet al. Localized CD47 blockade enhances immunotherapy for murine melanoma. Proc. Natl Acad. Sci. USA114(38), 10184–10189 (2017).
   PubMed Web of Science ®Google Scholar
• Kwong LS , BrownMH, BarclayAN, HatherleyD. Signal-regulatory protein α from the NOD mouse binds human CD47 with an exceptionally high affinity-implications for engraftment of human cells. Immunology143(1), 61–67 (2014).
   PubMed Web of Science ®Google Scholar
• Strowig T , RongvauxA, RathinamCet al. Transgenic expression of human signal regulatory protein alpha in Rag2−/− γc−/− mice improves engraftment of human hematopoietic cells in humanized mice. Proc. Natl Acad. Sci. USA108(32), 13218–13223 (2011).
   PubMed Web of Science ®Google Scholar
• Rongvaux A , WillingerT, MartinekJet al. Development and function of human innate immune cells in a humanized mouse model. Nat. Biotechnol.32(4), 364–372 (2014).
   PubMed Web of Science ®Google Scholar
• Aguiar PN Jr , De MelloRA, HallP, TadokoroH, Lima LopesG. PD-L1 expression as a predictive biomarker in advanced non-small-cell lung cancer: updated survival data. Immunotherapy9(6), 499–506 (2017).
   PubMed Web of Science ®Google Scholar
• Büttner R , GosneyJR, SkovBGet al. Programmed death-ligand 1 immunohisto-chemistry testing: a review of analytical assays and clinical implementation in non-small-cell lung cancer. J. Clin. Oncol.35(34), 3867–3876 (2017).
   PubMed Web of Science ®Google Scholar